Drug Approval | December 14, 2024
Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy
Final decision from the European Commission is anticipated within the coming months
Final decision from the European Commission is anticipated within the coming months
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
CSPC will receive an upfront payment of $100 million from AstraZeneca
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
ALS patients experience neuroinflammation and rapid neurodegeneration
Subscribe To Our Newsletter & Stay Updated
